Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.

Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37722656

about

Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Selective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2)The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer: a systematic review and meta-analysis.Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division.Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies.Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis.Interactome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells.

P2860

Q26781365-4FECA2D9-2ED0-467C-84D4-55471E144BBF Q28548419-EB9461EE-39CD-4F6A-A587-B2699111B255 Q35095549-1DC51B5A-70BF-4A51-BA11-9B7907D58190 Q35746819-07B7ECF9-B530-4D04-A38C-64F307F6CA32 Q36787517-9972EEF3-9CE3-4B94-8863-36458721C590 Q41472858-FAD89DC9-3669-43B9-AB00-CBAB43C3B0FC Q42316693-FB0E87E1-A914-4531-A29B-663C36B87EF2 Q47288270-B5B87F57-B09A-44DD-90EE-A3820673D0B6

P2860

Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37722656

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Microtubule-targeting agents i ...... l in hepatocellular carcinoma.

@en

Microtubule-targeting agents i ...... l in hepatocellular carcinoma.

@nl

type

label

Microtubule-targeting agents i ...... l in hepatocellular carcinoma.

@en

Microtubule-targeting agents i ...... l in hepatocellular carcinoma.

@nl

prefLabel

Microtubule-targeting agents i ...... l in hepatocellular carcinoma.

@en

Microtubule-targeting agents i ...... l in hepatocellular carcinoma.

@nl

P1433

Q37722656-ECC3F83E-6B8C-4923-BA37-8B4F9331BC1E

P1476

Q37722656-480151CF-FDA2-4CFF-BB0A-E09AAB8C1DC9

P2093

Q37722656-61713405-0553-4606-947E-75F864B43954

Q37722656-EDA056BC-982A-40A0-8EAD-7F5CE737B42F

P2860

Q37722656-0048A085-70ED-4F6D-9C8B-34728931C8CB

Q37722656-051F7FC3-1247-4BB5-9846-7C5CAB6BC19B

Q37722656-075EB276-501C-4B04-B58B-627C9A1B3BEF

Q37722656-08556CF0-B63F-4D05-9825-071536BF5771

Q37722656-09410D86-2414-489F-B72D-BE9E488884C4

Q37722656-0C1D9344-DDFC-4E86-B455-BCD56F9BE93C

Q37722656-0C3A7D6B-4A11-4D00-9847-F21D29EBC49A

Q37722656-0F01AC33-C678-4796-A549-7D3839E3E297

Q37722656-107F083D-A1C5-4D28-9152-0F4B807D8C23

Q37722656-1351A4E7-5191-462F-AFE8-F275BBBF5B32

P304

Q37722656-3DBBB910-56C2-4088-AD6A-28ECE012E950

P31

Q37722656-5176325D-4E45-43BF-9828-462FCC40CDA2

P356

Q37722656-B6D0EDCA-03E7-4C6C-89F2-FC8505685D5E

P407

Q37722656-44872886-B7E8-4092-B215-F64630F9E1CC

P478

Q37722656-29E76DB5-9F5A-4453-9CD1-B6865719C955

P50

Q37722656-06478D2C-980A-4E2B-9683-BB4C35472D4C

Q37722656-79A9F4F7-C730-4A54-91E5-CF94C1E1EA1A

P577

Q37722656-80B06E3B-4E7D-4B6B-8DD0-4C00871F7720

P5875

Q37722656-AF5B1A77-8A94-47DF-AF61-68C54CBF9720

P698

Q37722656-28CC9636-FCA8-48D0-BDA3-95E28E89DC4E

P932

Q37722656-4496AAB0-9377-4334-9EBA-CDAFAD967BB1

P356

P1433

OncoTargets and Therapy

P1476

Microtubule-targeting agents i ...... l in hepatocellular carcinoma.

@en

P2093

Herbert H Loong

http://www.w3.org/2001/XMLSchema#string

Winnie Yeo

http://www.w3.org/2001/XMLSchema#string

P2860

Microtubule-binding agents: a dynamic field of cancer therapeutics.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer

An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma

Microtubules as a target for anticancer drugs

Current development of mTOR inhibitors as anticancer agents

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

P304

575-585

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S46019

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262021011

http://www.w3.org/2001/XMLSchema#string

P698

24790457

http://www.w3.org/2001/XMLSchema#string

P932

3999274

http://www.w3.org/2001/XMLSchema#string